Absci Corp., the Vancouver-based company behind the multifaceted drug development platform. It was made public on Thursday. It's another sign of interest in new approaches to drug development, a traditionally risky business.

Absci focuses on SLOT XO accelerating drug development in the preclinical phase. The company has developed and acquired a number of tools that can predict drug candidates. Identify possible treatment goals and

testing therapeutic proteins on billions of cells and identify what is worth tracking.Sean McClain, Absci Founder, said, “We are delivering an end-to-end, end-to-end solution for drug development. “Think of this as a Google index search for protein drug discovery and bioproduction.